We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Indications and Limitations of Vismodegib for Basal Cell Carcinoma

Vivian T. Yin, MD1; Matthew Sniegowski, MD1; Bita Esmaeli, MD1
[+] Author Affiliations
1Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston
JAMA Ophthalmol. 2014;132(7):905-906. doi:10.1001/jamaophthalmol.2014.1787.
Text Size: A A A
Published online


To the Editor Gill et al1 reported the use of vismodegib in 7 patients with recurrent periocular and orbital basal cell carcinoma (BCC). Similar to the landmark 2012 study by Sekulic et al2 of 33 patients with metastatic and locally advanced BCC treated with vismodegib, the authors found an overall response rate of 57.1% (4 of 7 patients) with a median follow-up of 8 months compared with 43% in the phase 2 study. The authors state that this was the first series of periocular and orbital BCC cases treated with vismodegib; however, previous reviews have been published on the use of vismodegib for periocular lesions,3 and the 2012 study by Sekulic and colleagues included periocular lesions.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...